Tandem Diabetes Care
Stock Forecast, Prediction & Price Target
Tandem Diabetes Care (TNDM) stock Price Target by analysts
$47.5
Potential upside: 336.17%
Tandem Diabetes Care price prediction
What is Tandem Diabetes Care stock analysts` prediction?
Tandem Diabetes Care stock forecast: Based on 4 Wall Street analysts` predicted price targets for Tandem Diabetes Care in the last 3 months, the avarage price target is $47.5, with a high forecast of $NaN. The average price target represents a 336.17% change from the last price of $10.89.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Tandem Diabetes Care stock Price Target by analysts
Full breakdown of analysts given Tandem Diabetes Care price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Jeff Johnson Robert W. Baird | 0% 0/3 | 10 months ago | $37 239.76% upside | $32.87 | StreetInsider | Previous targets (2) |
Lee Hambright Bernstein | 0% 0/1 | 10 months ago | $42 285.67% upside | $33.11 | StreetInsider | Previous targets (0) |
David Roman Goldman Sachs | 0% 0/1 | 11 months ago | $46 322.40% upside | $39.99 | Benzinga | Previous targets (0) |
Shagun Singh RBC Capital | 0% 0/1 | 11 months ago | $65 496.87% upside | $41.07 | TheFly | Previous targets (0) |
William Plovanic Canaccord Genuity | 0% 0/1 | about 1 year ago | $57 423.41% upside | $37.04 | TheFly | Previous targets (0) |
Matt Miksic Barclays | 0% 0/1 | about 1 year ago | $58 432.59% upside | $41.67 | TheFly | Previous targets (0) |
Matt O'Brien Piper Sandler | 0% 0/4 | about 1 year ago | $55 405.05% upside | $35.21 | TheFly | Previous targets (3) |
Jeff Johnson Robert W. Baird | 0% 0/3 | about 1 year ago | $39 258.12% upside | $35.21 | TheFly | Previous targets (2) |
Steven Lichtman Oppenheimer | 0% 0/1 | about 1 year ago | $58 432.59% upside | $47.03 | StreetInsider | Previous targets (0) |
Matthew Blackman Stifel Nicolaus | 50% 1/2 | over 1 year ago | $60 450.96% upside | $51.93 | StreetInsider | Previous targets (1) |
Brooks O’Neil Lake Street | 0% 0/2 | over 1 year ago | $75 588.70% upside | $49.32 | TheFly | Previous targets (1) |
Matt O'Brien Piper Sandler | 0% 0/4 | over 1 year ago | $50 359.13% upside | $36.56 | TheFly | Previous targets (3) |
Jeff Johnson Robert W. Baird | 0% 0/3 | over 1 year ago | $36 230.57% upside | $36.56 | TheFly | Previous targets (2) |
Lawrence Biegelsen Wells Fargo | 0% 0/1 | over 1 year ago | $45 313.22% upside | $37.55 | StreetInsider | Previous targets (0) |
Danielle AntalffyMike Kratky Leerink Partners | 0% 0/1 | over 1 year ago | $45 313.22% upside | $35.35 | StreetInsider | Previous targets (0) |
Matthew Blackman Stifel Nicolaus | 50% 1/2 | over 1 year ago | $40 267.30% upside | $31.73 | StreetInsider | Previous targets (1) |
Kenneth Leon CFRA | 100% 1/1 | over 1 year ago | $36 230.57% upside | $33.87 | StreetInsider | Previous targets (0) |
Mathew Blackman Stifel Nicolaus | 100% 1/1 | over 1 year ago | $37 239.76% upside | $30.1 | TheFly | Previous targets (0) |
Jayson Bedford Raymond James | 0% 0/1 | about 3 years ago | $92 744.81% upside | $52.81 | Pulse 2.0 | Previous targets (0) |
Larry Biegelsen Wells Fargo | 100% 1/1 | about 3 years ago | $49 349.95% upside | $60.1 | TheFly | Previous targets (0) |
Matt O'Brien Piper Sandler | 0% 0/4 | about 3 years ago | $80 634.61% upside | $68.97 | TheFly | Previous targets (3) |
Brooks O’Neil Lake Street | 0% 0/2 | about 3 years ago | $200 1736.54% upside | $56.41 | Pulse 2.0 | Previous targets (1) |
Matt O'Brien Piper Sandler | 0% 0/4 | over 3 years ago | $120 1001.92% upside | $94.43 | TheFly | Previous targets (3) |
Travis Steed Bank of America Securities | 0% 0/1 | over 3 years ago | $130 1093.75% upside | $112.96 | Pulse 2.0 | Previous targets (0) |
Josh Jennings Cowen & Co. | 100% 1/1 | almost 4 years ago | $141 1194.76% upside | $132.51 | StreetInsider | Previous targets (0) |
Ravi Misra Berenberg Bank | 100% 1/1 | almost 4 years ago | $147 1249.86% upside | $132.51 | Investing | Previous targets (0) |
Alexander Nowak Craig-Hallum | 100% 1/1 | about 4 years ago | $153 1304.95% upside | $109.97 | StreetInsider | Previous targets (0) |
Matthew Taylor UBS | 0% 0/1 | about 4 years ago | $160 1369.23% upside | $109.97 | StreetInsider | Previous targets (0) |
Tandem Diabetes Care Financial Estimates
Tandem Diabetes Care Revenue Estimates
Tandem Diabetes Care EBITDA Estimates
Tandem Diabetes Care Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $702.79M N/A | $801.21M 14.00% | $747.71M -6.67% | Avg: $961.24M Low: $937.37M High: $1.01B avg. 28.55% | Avg: $1.05B Low: $1.03B High: $1.10B avg. 9.78% | Avg: $1.22B Low: $1.20B High: $1.28B avg. 16.47% | Avg: $1.24B Low: $1.21B High: $1.30B avg. 1.13% |
Net Income
% change YoY
| $15.56M N/A | $-94.59M -707.69% | $-222.61M -135.33% | Avg: $-74.52M Low: $-93.55M High: $-29.88M avg. 66.52% | Avg: $-41.30M Low: $-64.31M High: $3.24M avg. 44.57% | Avg: $-8.19M Low: $-8.71M High: $-7.98M avg. 80.15% | Avg: $4.22M Low: $4.11M High: $4.49M avg. 151.53% |
EBITDA
% change YoY
| $22.65M N/A | $-30.77M -235.83% | $-194.65M -532.61% | Avg: $-43.52M Low: $-45.92M High: $-42.44M avg. 77.64% | Avg: $-47.77M Low: $-50.13M High: $-46.82M avg. -9.78% | Avg: $-55.64M Low: $-58.38M High: $-54.53M avg. -16.47% | Avg: $-56.28M Low: $-59.04M High: $-55.15M avg. -1.13% |
EPS
% change YoY
| $0.25 N/A | -$1.47 -688% | -$3.43 -133.33% | Avg: -$1.11 Low: -$1.44 High: -$0.46 avg. 67.54% | Avg: -$0.62 Low: -$0.99 High: $0.05 avg. 44.26% | Avg: -$0.13 Low: -$0.13 High: -$0.12 avg. 79.66% | Avg: $0.07 Low: $0.06 High: $0.07 avg. 151.53% |
Operating Expenses
% change YoY
| $353.56M N/A | $474.79M 34.28% | $600.92M 26.56% | Avg: $409.62M Low: $399.45M High: $432.20M avg. -31.83% | Avg: $449.68M Low: $440.66M High: $471.80M avg. 9.78% | Avg: $523.75M Low: $513.24M High: $549.51M avg. 16.47% | Avg: $529.69M Low: $519.06M High: $555.75M avg. 1.13% |
FAQ
What is Tandem Diabetes Care stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 85.69% in 2025-2028.
We have gathered data from 11 analysts. Their low estimate is -93.55M, average is -74.52M and high is -29.88M.
What is Tandem Diabetes Care stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 13.98% in 2025-2028.
We have gathered data from 12 analysts. Their low revenue estimate is $937.37M, average is $961.24M and high is $1.01B.
What is Tandem Diabetes Care stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 85.75% in 2025-2028.
We have gathered data from 11 analysts. Their low earnings per share estimate is -$1.44, average is -$1.11 and high is $-0.46.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Tandem Diabetes Care stock. The most successful analyst is Jeff Johnson.